Surovatamig en tant que thérapie de consolidation chez les participants atteints de leucémie lymphoïde chronique ou de lymphome lymphocytaire à petites cellules avec chaîne lourde d'immunoglobuline variable (IGHV) non mutée (SOUNDTRACK-C1)
Une étude de phase III, randomisée, ouverte, multicentrique, sur le surovatamig en tant que traitement de consolidation par rapport à l’observation après un traitement d’induction de première ligne chez des participants atteints de leucémie lymphoïde chronique ou de lymphome lymphocytaire à petites cellules avec IGHV non muté (SOUNDTRACK-C1)
The purpose of this study is to evaluate the therapeutic benefit and safety of subcutaneous (SC) Surovatamig monotherapy as consolidation therapy in patients with Chronic Lymphocytic Leukaemia (CLL)/ Small Lymphocytic Lymphoma (SLL) with unmutated IGHV (uIGHV).
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This is a Phase III global, randomised, open-label, multicentre study. The study will consist of 2 sequential parts- the Dose Optimisation and Safety Run-in part and the Phase-III part.
During the dose optimisation and safety run-in part, Surovatamig will be initiated in 2 dose levels. This part will help to determine the recommended phase III dose (RP3D) of Surovatamig to be used in Phase III part. Phase III would comprise of 2 arms, Arm A where the Surovatamig dose (RP3D) will be administered as a consolidation therapy (post standard of care [SOC] induction therapy) and Arm B where participants will be observed. In Phase 3 participants will be randomized in a 1:1 ratio to Arm A or Arm B.
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: AstraZeneca Clinical Study Information Center
- Numéro de téléphone: 1-877-240-9479
- E-mail: information.center@astrazeneca.com
Lieux d'étude
-
-
-
Adelaide, Australie, 5000
- Recrutement
- Research Site
-
Fitzroy, Australie, 3065
- Pas encore de recrutement
- Research Site
-
Heidelberg, Australie, 3084
- Recrutement
- Research Site
-
Nedlands, Australie, 6009
- Recrutement
- Research Site
-
Perth, Australie, 6847
- Recrutement
- Research Site
-
Rockingham, Australie, 6168
- Pas encore de recrutement
- Research Site
-
-
-
-
Alberta
-
Calgary, Alberta, Canada, T2N 5G2
- Recrutement
- Research Site
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 4E6
- Suspendu
- Research Site
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3H 2Y9
- Recrutement
- Research Site
-
-
Ontario
-
Hamilton, Ontario, Canada, L8V 5C2
- Pas encore de recrutement
- Research Site
-
Toronto, Ontario, Canada, M5G 2L7
- Recrutement
- Research Site
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Recrutement
- Research Site
-
Montreal, Quebec, Canada, H2L 4M1
- Suspendu
- Research Site
-
Québec, Quebec, Canada, G1J 1Z4
- Suspendu
- Research Site
-
-
-
-
-
Edinburgh, Royaume-Uni, EH4 2XU
- Recrutement
- Research Site
-
Hampshire, Royaume-Uni, SO16 6YD
- Recrutement
- Research Site
-
Leeds, Royaume-Uni, LS9 7TF
- Pas encore de recrutement
- Research Site
-
London, Royaume-Uni, SE5 9RS
- Recrutement
- Research Site
-
London, Royaume-Uni, NW1 2BU
- Recrutement
- Research Site
-
Manchester, Royaume-Uni, M20 4BX
- Recrutement
- Research Site
-
Nottingham, Royaume-Uni, NG5 1PB
- Recrutement
- Research Site
-
Oxford, Royaume-Uni, OX3 7LE
- Recrutement
- Research Site
-
Sutton, Royaume-Uni, SM2 5PT
- Recrutement
- Research Site
-
-
-
-
-
Adapazarı, Turquie (Türkiye), 54100
- Recrutement
- Research Site
-
Antalya, Turquie (Türkiye), 07025
- Recrutement
- Research Site
-
Istanbul, Turquie (Türkiye), 34098
- Pas encore de recrutement
- Research Site
-
Istanbul, Turquie (Türkiye), 34899
- Recrutement
- Research Site
-
Istanbul, Turquie (Türkiye), 34517
- Recrutement
- Research Site
-
Kocaeli, Turquie (Türkiye), 41380
- Recrutement
- Research Site
-
Mezitli, Turquie (Türkiye), 33200
- Recrutement
- Research Site
-
-
-
-
California
-
La Jolla, California, États-Unis, 92093
- Pas encore de recrutement
- Research Site
-
-
Colorado
-
Denver, Colorado, États-Unis, 80218
- Pas encore de recrutement
- Research Site
-
-
Connecticut
-
New Haven, Connecticut, États-Unis, 06510
- Pas encore de recrutement
- Research Site
-
-
Illinois
-
Chicago, Illinois, États-Unis, 60637
- Pas encore de recrutement
- Research Site
-
-
Kansas
-
Kansas City, Kansas, États-Unis, 66210
- Pas encore de recrutement
- Research Site
-
-
Kentucky
-
Louisville, Kentucky, États-Unis, 40207
- Pas encore de recrutement
- Research Site
-
-
Maryland
-
Bethesda, Maryland, États-Unis, 20817
- Pas encore de recrutement
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, États-Unis, 02215
- Pas encore de recrutement
- Research Site
-
-
Minnesota
-
Rochester, Minnesota, États-Unis, 55905
- Pas encore de recrutement
- Research Site
-
-
New Jersey
-
Basking Ridge, New Jersey, États-Unis, 07920
- Pas encore de recrutement
- Research Site
-
-
New York
-
Rochester, New York, États-Unis, 14642
- Pas encore de recrutement
- Research Site
-
-
Ohio
-
Cleveland, Ohio, États-Unis, 44195
- Pas encore de recrutement
- Research Site
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, États-Unis, 15232
- Pas encore de recrutement
- Research Site
-
-
Texas
-
Houston, Texas, États-Unis, 77030
- Pas encore de recrutement
- Research Site
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Documented diagnosis of CLL/SLL with genomic features defined by unmutated IGHV.
- Treatment received and response at the end of 1L (first-line) finite therapy.
- Participants with SLL (except those in CR in Phase III part) must have measurable disease (nodal or extranodal) with at least one measurable target lesion.
- ECOG performance status of 0 to 2.
- Adequate haematologic, liver, renal and cardiac function.
- Female participants: must be either women not of childbearing potential or must use a highly effective form of contraception.
- Male participants who intend to be sexually active with females of childbearing potential must agree to use barrier contraception (eg, condoms).
Exclusion Criteria:
- Suspected or confirmed transformation of CLL/SLL to a more aggressive form of lymphoma (ie, Richter's transformation, prolymphocytic leukaemia, or DLBCL).
- Evidence of active or history of Central Nervous System (CNS) involvement by CLL/SLL.
- History of or ongoing confirmed progressive multifocal leukoencephalopathy.
- Participants who have any concurrent or history of malignancy.
- Participants with:
- Active or uncontrolled infection (including Epstein-Barr virus-EBV) requiring systemic therapy.
- Participants with known history of Heamophagocytic lymphohistiocytosis (HLH).
- Human Immunodeficiency Virus (HIV) infection, or participants with chronic or active infection with Hepatitis B Virus (HBV) or Hepatitis C Virus (HCV).
- Major cardiac abnormalities.
- Prior CLL/SLL-specific therapies.
- Requires chronic immunosuppressive therapy for active autoimmune/inflammatory condition or prior allogeneic stem cell or solid organ transplant.
- Major surgical procedure.
- Known hypersensitivity to surovatamig or any of the excipients of the product.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation séquentielle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Dose Optimisation and Safety run-in (DOSRI)- Surovatamig Dose 1
Participants will receive Surovatamig Dose 1 subcutaneously (SC) for 6 cycles (each cycle is 28 days in length). |
Surovatamig will be administered as a subcutaneous injection.
Autres noms:
|
|
Expérimental: DOSRI-Surovatamig Dose 2
Participants will receive Surovatamig Dose 2 SC for 6 cycles (each cycle is 28 days in length). |
Surovatamig will be administered as a subcutaneous injection.
Autres noms:
|
|
Expérimental: Phase III-Arm A: Surovatamig SC
Participants will receive Surovatamig at RP3D subcutaneously for 6 cycles (each cycle is 28 days in length). |
Surovatamig will be administered as a subcutaneous injection.
Autres noms:
|
|
Aucune intervention: Phase III-Arm B: Observation
Participants will undergo observation for 24 weeks. |
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
DOSRI- Number of participants with adverse events (AEs) and Serious Adverse Events (SAEs)
Délai: Up to 5 years
|
To assess the safety and tolerability of SC surovatamig as consolidation therapy using dose optimisation in CLL/SLL participants with uIGHV. Also, to determine the RP3D of SC surovatamig monotherapy as consolidation therapy in CLL/SLL participants with uIGHV. |
Up to 5 years
|
|
Phase III- Progression Free Survival (PFS)
Délai: Until disease progression or death (up to 5 years)
|
PFS is defined as the time from date of randomisation until disease progression or death due to any cause, whichever occur first based on International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018 criteria, as assessed by independent review committee (IRC). |
Until disease progression or death (up to 5 years)
|
|
DOSRI- Number of participants with study intervention discontinuations, dose reductions and dose delays due to AEs
Délai: Up to 5 years
|
To assess the safety and tolerability of SC surovatamig as consolidation therapy using dose optimisation in CLL/SLL participants with uIGHV. Also, to determine the RP3D of SC surovatamig monotherapy as consolidation therapy in CLL/SLL participants with uIGHV. |
Up to 5 years
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Objective Response Rate (ORR)
Délai: Up to 5 years
|
ORR is defined as the proportion of participants achieving either a partial response (PR) or complete response (CR)/complete response with incomplete haematological recovery (CRi) based on response criteria iwCLL 2018, as assessed by IRC or investigator at any point during therapy/observation. |
Up to 5 years
|
|
Complete Response rate (CR rate)
Délai: Up to 5 years
|
CR rate is defined as the proportion of participants achieving a CR or CRi as best response based on response criteria for iwCLL 2018. |
Up to 5 years
|
|
Duration of response (DoR)
Délai: Up to 5 years
|
The DoR is defined as the time from the date of first documented response until date of documented progression based on response criteria for iwCLL 2018. |
Up to 5 years
|
|
DOSRI- PFS
Délai: Until disease progression or death (up to 5 years)
|
PFS for Safety Run-in phase is defined as the time from first dose until the date of documented progression or death due to any cause whichever comes first, based on iwCLL 2018 criteria. |
Until disease progression or death (up to 5 years)
|
|
Overall Survival (OS)
Délai: Up to 5 years
|
OS is defined as the time from first dose until death due to any cause. |
Up to 5 years
|
|
Serum concentrations of Surovatamig
Délai: At pre-defined intervals from date offirst dose (C1D1) up to 30 days from last dose (approximately 5 years)
|
To characterise the serum concentration of SC surovatamig as consolidation therapy in CLL/SLL participants with uIGHV. |
At pre-defined intervals from date offirst dose (C1D1) up to 30 days from last dose (approximately 5 years)
|
|
Maximum concentration observed (Cmax)
Délai: At pre-defined intervals from date of first dose up to 30 days from last dose (approximately 5 years)
|
To characterise the pharmacokinetics (PK) of SC surovatamig as consolidation therapy in CLL/SLL participants with uIGHV. |
At pre-defined intervals from date of first dose up to 30 days from last dose (approximately 5 years)
|
|
Time to Maximum Concentration (tmax)
Délai: At pre-defined intervals from date of first dose up to 30 days from last dose (approximately 5 years)
|
To characterise the PK of SC surovatamig as consolidation therapy in CLL/SLL participants with uIGHV. |
At pre-defined intervals from date of first dose up to 30 days from last dose (approximately 5 years)
|
|
Trough concentration (Ctrough)
Délai: At pre-defined intervals from date of first dose up to 30 days from last dose (approximately 5 years)
|
To characterise the PK of SC surovatamig as consolidation therapy in CLL/SLL participants with uIGHV. |
At pre-defined intervals from date of first dose up to 30 days from last dose (approximately 5 years)
|
|
Number of participants with Anti-drug antibodies (ADA)
Délai: At predefined intervals from the date of first dose to approximately 5 years
|
DOSRI- To evaluate the immunogenicity of SC surovatamig as consolidation therapy in CLL/SLL participants with uIGHV. Phase III- To determine the immunogenicity of SC surovatamig in CLL/SLL participants with uIGHV. |
At predefined intervals from the date of first dose to approximately 5 years
|
|
Phase III- PFS
Délai: Until disease progression or death (up to 5 years)
|
PFS is defined as the time from date of randomisation until disease progression or death due to any cause , whichever comes first based on iwCLL 2018 criteria, as assessed by investigator. |
Until disease progression or death (up to 5 years)
|
|
Phase III- Number of participants with AEs and SAEs
Délai: Up to 5 years
|
To assess safety and tolerability of SC surovatamig compared to observation in CLL/SLL participants with uIGHV. |
Up to 5 years
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- D7409C00001
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment:
https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Délai de partage IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Critères d'accès au partage IPD
When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org.
Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .